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-Hexylcarbamoyl-5-ﬂuorouracil
PubChem CID: 2577)
-Fluorouracil (PubChem CID: 3385)
a  b  s  t  r  a  c  t
Addition  of  DMPC  considerably  inhibits  the  degradation  of  Carmofur  in  neutral  phosphate
buffer  solutions  and  this  drug  becomes  less  inﬂuenced  by pH.  Carmofur  stabilization  at
neutral  pH  caused  by  DMPC  addition  for  in  vitro  studies  was  characterized  and  monitored  by
1H  NMR.  Antiproliferative  activity  studies  on  various  tumor  cell  lines showed  considerable
increase  of  Carmofur  ability  to prevent  tumor  cell  growth,  when  it is added  as  a  mixture
with  DMPC.  This  technique  opens  a way  for Carmofur  drug  delivery  in neutral  and  basic
media.
© 2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
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. Introduction
Carmofur (1-hexylcarbamoyl-5-ﬂuorouracil, HCFU,
ifurol) is one of the masked forms of 5-ﬂuorouracil
idely used as an antineoplastic agent. This drug, in its
ral form, has been used as adjuvant chemotherapy for
uratively resected colorectal cancer patients. Trials have
Abbreviations: DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine;
armofur, 1-hexylcarbamoyl-5-ﬂuorouracil; 5-Fu, 5-ﬂuorouracil; NMR,
uclear magnetic resonance.
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
icenses/by-nc-nd/4.0/).conﬁrmed that the drug is effective on patients with this
cancer type, extending their survival [1,2]. The Carmofur
molecule contains an active core of 5-ﬂuorouracil and
hexylcarbamoyl substituent as a transport form, and it
helps 5-FU to penetrate into the cell. In the last years
the interest in encapsulation of 5-ﬂuorouracil derivatives
in liposomal formulations was  increased [3]. Liposomal
5-FU microspheres are potent in the treatment of liver
metastases increasing the intratumoral concentration of
5-FU up to 2203 times [4]. Recently, experimental research
concerning antitumor activity of Carmofur water solu-
bilized by lactic acid oligomer-grafted pullulan nanogels
has been reported. Nanogel with Carmofur showed a
strong suppressive effect of tumor cells grown, in contrast
cess article under the CC BY-NC-ND license (http://creativecommons.org/
cology R378 I. Domracheva et al. / Toxi
to the Carmofur solution [5]. Treatment of colorectal
cancer using a combination of liposomal irinotecan and
5-ﬂuorouracil leads to exposition time prolongation and
improves antitumor activity [6]. The main disadvantages
of Carmofur is its low solubility; moreover, this drug
relatively easily hydrolyzes under physiological conditions
with pH > 7.0. Therefore the scope for use of this drug is
signiﬁcantly narrowed. However, nanogels of HCFU have
been formulated previously by cross-linked polymeric
micelles of N-isopropylacrylamide and N-vinylpyrrolidone
and higher accumulation of HCFU in brain was reported
[7,8]. As well as Carmofur loaded pluronic polymeric
micelles were produced and characterized [9].
Our experience with the chemistry of nucleosides
[10,11] and antitumor activity studies [12–14] inspired
us to investigate the stability of Carmofur (1) in aqueous
phosphate buffer solutions at pH from 5.0 to 8.0 and 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) inﬂu-
ence on Carmofur stability monitored by 1H NMR.
2. Materials and methods
Carmofur was purchased from TCI, DMPC was pur-
chased from NOF Corporation (Tokyo, Japan) and used
without further puriﬁcation. 1H NMR  spectra of 1 were run
on a Varian-Mercury BB 400 MHz  spectrometer at 298 K,
with a standard pulse sequence WET  for residual water
signal suppression. The spectral parameters were: 4695 Hz
spectral width, 16K complex data points, number of scans
128, acquisition time 3.5 s, digital resolution 0.007 Hz and
relaxation delay 2 s. The acquired FIDs were processed with
zero-ﬁlling to 32 K.
2.1. Stability studies by NMR
For integration the C6H signals of 1 (1A + 1B)  was  used.
The samples were prepared in phosphate buffers in D2O at
pH 5.0–8.0; the difference of pH values in D2O and H2O
water buffers were less than 0.4. Each of the 8 experi-
ments with a speciﬁc concentration of HCFU was single
point. 86.87 mg  (0.338 M)  of HCFU was dissolved in 1 ml  of
chloroform-d1 (CDCl3). The sample was stored in the fridge
at 4 ◦C in the container with a cap-sung. For the sample
preparation 15 l of solution of CHFU in CDCl3 were taken
by the gamiltanian syringe and added to the vial with buffer
liposomes. Then the sample was thoroughly shaken and
put into the NMR  spectrometer. The temperature inside the
NMR spectrometer was 25 ◦C and it was controled by the
integrated thermometer. Each spectrum was acquired with
t2max = 3.49 s, the relaxation delay was 2 s, and the num-
ber of scans was 128. The chemical shifts of the hydrogen
atoms of 1 are presented in ppm and referred to the resid-
ual signals of CDCl3 ı = 7.26 and D2O ı = 4.5 (1H) ppm. 1H
NMR (CDCl3, 400 MHz) ı (ppm): 0.87 (3H, t, J = 7.2, CH3),
1.73–1.28 (6H, m,  3CH2), 1.59 (2H, m,  J = 7.2, CH2), 3.37 (2H,
td, J = 7.2, J = 5.1, NCH2), 8.42 (1H, d, J = 6.9, CH), 8.91 (1H,
br s, NH), 8.96 (1H, t, J = 5.1, NH).2.2. DMPC vesicles preparation for NMR  studies
DMPC has been dissolved in buffer/water and then soni-
cated by Ultrasonic Processor Cole Parmer© CPX130 witheports 2 (2015) 377–383
30% of power for 5 min  with on/off cycle of 10 s. Then to
the 800 l of the vesicle’s solution in the 5 mm NMR tube
15 l of 1 dissolved in CDCl3 with concentration 0.337 M
has been added. The resulting mixture was then immedi-
ately inserted into spectrometer.
2.3. Computational details
All HF calculations were performed in Jaguar 8.0 (release
515) from Schrödinger [15]. The basis set was  6-311G**++.
Geometries were optimized in the gas phase, and energies
in solvent were calculated using the Poisson–Boltzmann
ﬁnite-element (PBF) [16,17] implicit solvation model at the
optimized gas phase geometries.
2.4. Preparation of DMPC vesicles with 1 for in vitro
studies (3)
Carmofur (26 mg,  0.1 mmol) and DMPC (0.334 g,
0.5 mmol) were dissolved in 25 ml  of chloroform and evap-
orated on rotatory evaporator under reduced pressure with
slow rotation without any heating. Then additional portion
of chloroform was  added and the procedure was  repeated
for 5 times.
2.5. In vitro cytotoxicity assay
Monolayer tumor cell line: HT-1080 (human connec-
tive tissue ﬁbrosarcoma), C6 (rat glial tumor), SH-SY-5Y
(human neuroblastoma), MH-22A (mouse hepatoma),
MDA-MB-435s (human melanoma), MCF-7 (human breast
adenocarcinoma, estrogen-positive), and normal cell lines:
H9C2 (rat myocardium) and NIH 3T3 (Mouse Swiss Albino
embryo ﬁbroblasts) were grown in standard medium
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS, “Sigma”).
About 1–2 × 104 cells/well (depending on line nature) were
placed in 96-well plates immediately after compounds
(250, 50, 10, 2, 0.4 and 0.08 M)  were added to the wells.
The control cells without test compounds were cultured
on separate plate. The plates were incubated for 72 h, at
37 ◦C, 5% CO2. The number of surviving cells was deter-
mined using MTT  (thiazolyl blue tetrazolium bromide), and
OD was read  = 540 nm.  The IC50 was  calculated using
program Graph Pad Prism® 3.0, r < 0.05. The control cells
without test compounds were cultured on separate plate
and an appropriate volume of control buffer was  added to
control cells. Each assay was conducted in triplicate.
2.6. Standard operating procedure (SOP) for the Balb/c
3T3 neutral red uptake cytotoxicity test – a test for basal
cytotoxicity
The SOP was submitted in 1992 to INVITTOX, where
it is still available as Protocol No. 46 (NRU Assay). The
NRU cytotoxicity assay procedure is a cell survival/viability
chemosensitivity assay based on the ability of viable cells
to incorporate and bind neutral red, a supra-vital dye. The
basal cytotoxicity is to be used to predict starting doses
for in vivo acute oral LD50 values in rodent. Using the 3T3
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ell line the borderline concentration, relevant to the high-
st tolerated dose, is determined for each material. NIH
T3 (normal mouse ﬁbroblasts) cells were grown in DMEM
edium supplemented with 10% FBS. Before compounds
1000, 316, 100, 31, 10, 3, 1 g/ml) were added to the wells
 × 104 cells/well were placed in 96-well plates for 24 h.
he plates were then incubated for 24 h, 37 ◦C, 5% CO2. The
ells were incubated then with neutral red dye for 4 h and
D was read,  = 540 nm.  This method is alternative to LD50
n vivo. LD50 values (LD50 value is amount of the drug that
s taken to kill 50% of test animals) was calculated accord-
ng to the formula: log(LD50) [mmol/kg] = 0.435 × log(IC50)
mmol/l] = 0.625.
. Results and discussion
Being a potentially tautomeric system 1 can exist in
hree tautomeric interconverting structures (Scheme 1).
automers fall in line with the stability sequence:
,4-dioxo > 2-hydroxy-4-oxo > 2-oxo-4-hydroxy, and the
resence of water does not affect the relative stabilities
s found in the gas phase [18]. Experimental data suggest
19], that the dioxo-tautomer of 5-FU is stable in the solid
tate, gas phase and in aprotic solutions. The same could
e extrapolated for 5-ﬂuorouracil fragment in Carmofur (1)
ig. 1. 1H NMR  spectra of the solution of 1 in phosphate buffers at different pH v
f  1A and 1B forms.ic forms of 1.
molecule. According to quantum-chemical calculations of
N1-substituted derivative modeling 1 the stability of diketo
form 1, with relative energy (E) equal to 0 kcal/mol, is
large enough as compared with the other tautomers 1A
(E = 12.3 kcal/mol) and 1B (E = 19.1 kcal/mol). It con-
ﬁrms that the dioxo tautomer of 1 is also the only important
tautomer in the gas phase and the same result is true for
the PBF water solution method. Fig. 1 demonstrates 1H
NMR  spectra of the solution of 1 in phosphate buffers at
different pH values. According to our studies in aqueous
phosphate buffer solutions tautomeric forms of 1 are signif-
icantly inﬂuenced by their pH value. Increase of pH favors
the transformation of diketo form to 2- and 4-hydroxy tau-
tomers (1A and 1B).
Being one of the masked forms of 5-ﬂuorouracil, 1 is
extremely susceptible to base catalyzed hydrolysis in aque-
ous solutions to 5-ﬂuorouracil (1 is the most stable at
pH ∼ 4) [20]. In the course of the present study, the degra-
dation of Carmofur in water phosphate buffer solutions was
found to be rather accelerated by increasing the pH value of
the phosphate buffer. Fig. 2 shows the time courses of the
degradation of 1 in the phosphate buffers with different pH
values. It is apparent that the degradation rate of Carmofur
at pH 8 and pH 7 is much faster, whereas the 1 molecule at
pH 5 is practically kept unharmed for more than 14 h.
alues. The high ﬁeld shift of C6H proton signal reﬂects the changing ratio
380 I. Domracheva et al. / Toxicology Reports 2 (2015) 377–383
at differFig. 2. Visualization of degradation of 1 in aqueous phosphate buffers 
concentration of 1.
Next, we attempted to stabilize 1 by addition of 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC). After
brief optimization of solubility for the further in vitro stud-
ies we decided to use 1:5 ratio of 1:DMPC (2). Experiments
were made by DMPC emulsiﬁcation in phosphate buffer
solutions in deuterated water and then sonicated by Ultra-
sonic Processor Cole Parmer© CPX130 with 30% of power
for 5 min  with on/off cycle of 10 s. Then to the 800 l
of the vesicle’s solution in a 5 mm NMR  tube 15 l of 1,
dissolved in CDCl3 with 0.337 M concentration, has been
added. The resulting mixture was immediately inserted
into spectrometer. Fig. 3 shows the effect of 2 additions
on the degradation of 1 in aqueous phosphate buffers. It
is apparent that 2 was rather effective in stabilization of 1.
Fig. 3 shows the remaining 1 (in %) after 14 h as a function of
pH. The stabilizing effect of 2 increased with decreasing pH
Fig. 3. Degradation of 1 with 2 in phosphate buffers with different pH monient pH values (monitored by 1H NMR). On y-axis C (mM) denotes the
and the degradation of 1 was completely prevented even
for 2 days.
The k values for the hydrolysis reactions of 1 at vari-
ous pH are presented in Table 1. The degradation rate of
1 can be described in terms of pseudo-ﬁrst-order kinetics.
The k values obtained indicate that Carmofur is chemically
more stable under acidic conditions and its degradation
rate grows on going from pH = 5.0 to pH = 8.0.
Addition of DMPC considerably inhibits the degrada-
tion of 1 and this drug becomes less inﬂuenced by pH. The
apparent ﬁrst order degradation rate constants of 1 in the
presence of 2 are summarized in Table 1. A tendency for the
inhibition increases with increasing pH value. The greater
stabilizing effect is observed for pH = 8.0, where inhibition
ratio rises by over 7 times as compared with the pure 1 solu-
tion at the same pH. The release of 5-ﬂuorouracil from 1 in
tored by 1H NMR. On y-axis C (mM) denotes the concentration of 1.
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Table  1
K  values and inhibition ratios for the hydrolysis reaction of 1 and 3 in phosphate buffers with different pH values.
pH
5.0 6.0 7.0 8.0
Rate constants, K (×104) 1 0 0.17 0.54 0.70
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he presence of DMPC has been signiﬁcantly reduced due
o that DMPC provides phospholipid environment around
he Carmofur molecules incorporated into DMPC nanopar-
icles.
Although it is known that the lifetime of liposomes in
ell culture media is around 200 min  [21] the form and size
f them is not primary; we decided to check the differ-
nce of liposomes made from DMPC (2) and the mixture of
armofur with DMPC (3) before in vitro tests using phase
ontrast invert microscope (Nikon Eclipse TE300). Vesicles
ormed by DMPC in phosphate buffer at pH = 7.2 are with
arious sizes, besides, liposomes of 3 are more organized
nd smaller by size (Fig. 4). Since the Carmofur molecule
as a lipophilic chain we propose that the inclusion of 1 in
eneral proceeds by intercalation.
In vitro cytotoxicity caused by Carmofur (1), DMPC (2),
armofur × 5DMPC (3) and 5-ﬂuorouracil was tested on
onolayer tumor cell lines: HT-1080 (human connec-ive tissue ﬁbrosarcoma), C6 (rat glial tumor), SH-SY-5Y
human neuroblastoma), MH-22A (mouse hepatoma),
DA-MB-435s (human melanoma), MCF-7 (human
reast adenocarcinoma, estrogen-positive), and H9C2 (rat
Fig. 4. Representative micrographs of DMPC 2 (A – 104; B – 107) and Carmofu0.05 0.09 0.09
3.40 5.96 7.74
myocardium). Using the NIH 3T3 (mouse ﬁbroblasts) cell
line the borderline concentration, relevant to the highest
tolerated dose, is determined for each compound. The basal
cytotoxicity is to be used to predict starting doses for in vivo
acute oral LD50 values in rodent [22]. The results of these
experiments are summarized in Table 2. 5-Fluorouracil
interferes with thymidylate synthesis, and has a broad
spectrum of activity against solid tumors. However, 5-FU
has limitations that include a short biological half-life
due to rapid metabolism, incomplete and non-uniform
oral absorption due to metabolism by dihydropyrimidine
dehydrogenase, toxic side effects on bone marrow and
the gastrointestinal tract, and non-selective action against
healthy cells [23].
Carmofur exhibits high cytotoxic activity on glioma
C6 (IC50 = 7 M)  cell line, however combination of Car-
mofur with 5 molecules of DMPC (3) has two times
more extended cytotoxic effect on C6 (IC50 = 3 M).  Similar
results were obtained by comparison of 1 and 3 cytotoxicity
on human neuroblastoma SH-SY-5Y cell line, IC50 = 76 M
and 22 M,  correspondingly. It should be noted that DMPC
showed no cytotoxic effect on these brain tumor cell lines.
r × 5DMPC 3 (C – 104; D – 107) taken by contrast invert microscope.
382 I. Domracheva et al. / Toxicology R
Table 2
In vitro cytotoxicity on monolayer tumor cell lines: HT-1080, C6, SH-
SY-5Y, MH-22A, MDA-MB-435s, MCF-7, H9C2, and NIH 3T3 caused by
Carmofur (1), DMPC (2), Carmofur × 5DMPC (3) and 5-ﬂuorouracil.
Cell line (1)a (2)a (3)a 5-Fluorouracila
C6 7 b 3 –
SHSY-5Y 76 214 22 107
MH-22A 43 b 27 –
MDA-MB-435s 213 231 68 31
MCF-7 230 b 81 46
HT-1080 67 20 14 14
H9C2 189 b 154 –
NIH3T3 184 b 45 –
LD50 (mg/kg)c 489 b 589 >2000
[
[a IC50, concentration (M) providing 50% cell killing effect.
b No cytotoxic effect.
c Starting dose.
Since 5-ﬂuorouracil based drugs usually cannot cross the
blood–brain barrier, it may  be assumed that the liposo-
mal  form 3 can serve as a drug delivery agent for the
treatment of brain tumors. Despite 5-ﬂuorouracil with-
out a transport form is useless for in vivo procedures,
we discovered its cytotoxic effect in vitro with a purpose
to compare its antiproliferative effect on tumor cells. 5-
Fluorouracil showed weak cytotoxic effect on SH-SY-5Y
cell line (IC50 = 107 M).  Less prominent difference was
observed by treatment of hepatoma MH-22A cells with 1
and 3 (IC50 = 43 M for 1, IC50 = 27 M for 3). This can be
attributed to the high ability to metabolize lipids by all
types of hepatic cells; as a result liposomes were destroyed
in shorter length of time. Notably, according to received
in vitro data concerning Carmofur (1) ability to prevent
growth of human melanoma MDA-MB-435s and estrogen
positive human breast adenocarcinoma MCF-7 we  can con-
clude that 1 showed no activity in vitro, however, Carmofur
was administered to patients in postoperative period with
early stage breast cancer [24]. Besides, 3 exhibit medium
antiproliferative effect on these breast cancer cell lines
(IC50 = 68 M and 81 M,  correspondingly). These data are
in agreement with previously reported studies [25]. In the
case of human connective tissue ﬁbrosarcoma HT-1080 we
discovered good cytotoxic effect caused by 3, however,
DMPC (2) surprisingly showed similar effect against HT-
1080 cells (IC50 = 20 M).  Recent studies demonstrated that
primary cardiomyocytes are a valuable tool for studying
the metabolic capacity of the heart. H9C2 cell line is a valu-
able in vitro model to study the drug metabolizing enzymes
in the heart [26]. Inspection of cytotoxicity of 1 and 3 led
us to conclude that both Carmofur and Carmofur × 5DMPC
are not cardiotoxic on H9C2. High cytotoxic effect on
mouse ﬁbroblasts NIH 3T3 caused by 3 can be explained
by expressed phagocytosal properties on this cell line.
4. Conclusions
To sum up, we discovered that the addition of DMPC
considerably inhibits the degradation of Carmofur in neu-
tral phosphate buffer solutions and this drug becomes less
inﬂuenced by pH. Antiproliferative activity studies showed
considerable increase of Carmofur ability to prevent tumor
cell growth, when it is added as a mixture with DMPC. The
[eports 2 (2015) 377–383
most expressed antiproliferative effect has been found
against glioma C6 cells (IC50 = 3 M).  Similar increasing of
cytotoxicity was  shown on human neuroblastoma SH-SY-
5Y cell line. On contrary to Carmofur, Carmofur × 5DMPC
mixture exhibits medium cytotoxic effect against human
melanoma MDA-MB-435s and estrogen positive human
breast adenocarcinoma MCF-7 cells. This technique opens
a way for the drug delivery of Carmofur in neutral and
basic media.
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